A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 34
- Registration Number
- NCT02115165
- Locations
- 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France
Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment
Not Applicable
- Conditions
- Interventions
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2016-06-10
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 2200
- Registration Number
- NCT02105168
- Locations
- 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France
Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 4
- Registration Number
- NCT02094391
- Locations
- 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France
Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 280
- Registration Number
- NCT02089100
- Locations
- 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val De Marne, France
Measurement of Cardiac Index Using an Implanted Central Venous Access Port in Patients Scheduled for Oncologic High-risk Surgery
Completed
- Conditions
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 33
- Registration Number
- NCT02063009
- Locations
- 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France
Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 195
- Registration Number
- NCT02044354
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France
Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 27
- Registration Number
- NCT02040064
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France
Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 29
- Registration Number
- NCT02025881
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷Gustave Roussy, Villejuif, Val De Marne, France
🇫🇷Centre Oscar Lambret, Lille, France
A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With Gemcitabine
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-23
- Last Posted Date
- 2016-07-12
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 52
- Registration Number
- NCT02018874
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France
Randomized Phase II Study to Assess PD 0332991 in Breast Cancer
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 132
- Registration Number
- NCT02008734
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France
© Copyright 2024. All Rights Reserved by MedPath